ReviewCurrent urology reports2015
What is the Need for Prostatic Biomarkers in Prostate Cancer Management?
Review in Current urology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Identification of novel prostate cancer genes in patients stratified by Gleason classification: Role of antitumoral genes.International journal of cancer · 2022Article
- Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification.BMC cancer · 2019Article
- Upregulation of Holliday junction recognition protein predicts poor prognosis and biochemical recurrence in patients with prostate cancer.Oncology letters · 2019Article
- Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies.Indian journal of surgical oncology · 2017Review
- mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.Oncotarget · 2016Article
- Splice Variants of Androgen Receptor and Prostate Cancer.Oncology reviews · 2016Review
- Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics.BMC medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Discriminating patients with a low risk of progression from those with lethal prostate cancer is one of the main challenges in prostate cancer management. Indeed, such discrimination is essential if we aim to avoid overtreatment in men with indolent disease and to improve survival in those men with lethal disease. We are reporting on the current literature on such prognostic tools that are now available, their clinical role and their limitations in individualizing care. There is an urgent need to incorporate such genomic tools into new platform-based clinical trial structures to further develop and validate prognostic and predictive biomarkers and provide prostate cancer patients with an effective and cost-efficient access to new drugs in the setting of personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.